TET2 mutation in diffuse large B-cell lymphoma.
Ten-eleven translocation-2 (TET2) mutation is frequently observed in myeloid malignancies, and loss-of-function of TET2 is essential for the initiation of malignant hematopoiesis. TET2 mutation presents across disease entities and was reported in lymphoid malignancies. We investigated TET2 mutations in 27 diffuse large B-cell lymphoma (DLBCL) patients and found a frameshift mutation in 1 case (3.7%). TET2 mutation occurred in some populations of DLBCL patients and was likely involved in the pathogenesis of their malignancies.
Department of Transfusion and Cell Therapy, University of Miyazaki Hospital.
Yoko
Y
Kubuki
Takumi
T
Yamaji
Tomonori
T
Hidaka
Takuro
T
Kameda
Kotaro
K
Shide
Masaaki
M
Sekine
Ayako
A
Kamiunten
Keiichi
K
Akizuki
Haruko
H
Shimoda
Yuuki
Y
Tahira
Kenichi
K
Nakamura
Hiroo
H
Abe
Tadashi
T
Miike
Hisayoshi
H
Iwakiri
Yoshihiro
Y
Tahara
Mitsue
M
Sueta
Shojiro
S
Yamamoto
Satoru
S
Hasuike
Kenji
K
Nagata
Akira
A
Kitanaka
Kazuya
K
Shimoda
D000368:Aged; D004268:DNA-Binding Proteins / Q000235:genetics*; D049308:Dioxygenases; D005260:Female; D016368:Frameshift Mutation; D019337:Hematologic Neoplasms / Q000209:etiology; D006410:Hematopoiesis; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000453:epidemiology / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011518:Proto-Oncogene Proteins / Q000235:genetics*
D004268:DNA-Binding Proteins; D011518:Proto-Oncogene Proteins; D049308:Dioxygenases; C541081:TET2 protein, human